Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab. One-year outcome in the EPILOG trial
Angioplasty, Balloon, Coronary
Immunoglobulin Fab Fragments
Platelet Aggregation Inhibitors
Platelet Glycoprotein GPIIb-IIIa Complex
Acute reductions in ischemic events after percutaneous coronary intervention by abciximab are sustained over follow-up to at least 1 year. Early periprocedural myocardial infarctions suppressed by this therapy are associated with long-term mortality rates.